| Style | Citing Format |
|---|---|
| MLA | Heydari F, et al.. "Platelet-Derived Mitochondrial Transfer in Cancer Metastasis: Mechanisms, Functional Consequences, and Translational Opportunities." Clinical and Experimental Metastasis, vol. 43, no. 5, 2026, pp. -. |
| APA | Heydari F, Fahmi S, Alqassimi S, Mansuri N, Al Samawi R I, Mozaffari F, Hamblin M R, Naghinezhad J (2026). Platelet-Derived Mitochondrial Transfer in Cancer Metastasis: Mechanisms, Functional Consequences, and Translational Opportunities. Clinical and Experimental Metastasis, 43(5), -. |
| Chicago | Heydari F, Fahmi S, Alqassimi S, Mansuri N, Al Samawi R I, Mozaffari F, Hamblin M R, Naghinezhad J. "Platelet-Derived Mitochondrial Transfer in Cancer Metastasis: Mechanisms, Functional Consequences, and Translational Opportunities." Clinical and Experimental Metastasis 43, no. 5 (2026): -. |
| Harvard | Heydari F et al. (2026) 'Platelet-Derived Mitochondrial Transfer in Cancer Metastasis: Mechanisms, Functional Consequences, and Translational Opportunities', Clinical and Experimental Metastasis, 43(5), pp. -. |
| Vancouver | Heydari F, Fahmi S, Alqassimi S, Mansuri N, Al Samawi R I, Mozaffari F, et al.. Platelet-Derived Mitochondrial Transfer in Cancer Metastasis: Mechanisms, Functional Consequences, and Translational Opportunities. Clinical and Experimental Metastasis. 2026;43(5):-. |
| BibTex | @article{ author = {Heydari F and Fahmi S and Alqassimi S and Mansuri N and Al Samawi R I and Mozaffari F and Hamblin M R and Naghinezhad J}, title = {Platelet-Derived Mitochondrial Transfer in Cancer Metastasis: Mechanisms, Functional Consequences, and Translational Opportunities}, journal = {Clinical and Experimental Metastasis}, volume = {43}, number = {5}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Heydari F AU - Fahmi S AU - Alqassimi S AU - Mansuri N AU - Al Samawi R I AU - Mozaffari F AU - Hamblin M R AU - Naghinezhad J TI - Platelet-Derived Mitochondrial Transfer in Cancer Metastasis: Mechanisms, Functional Consequences, and Translational Opportunities JO - Clinical and Experimental Metastasis VL - 43 IS - 5 SP - EP - PY - 2026 ER - |